Found 37 results
Filters: Keyword is AIDS Vaccines  [Clear All Filters]
Doores KJ, Huber M, Le KM, Wang S-K, Doyle-Cooper C, Cooper A, Pantophlet R, Wong C-H, Nemazee D, Burton DR.  2013.  2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.. J Virol. 87(4):2234-41.
Ota T, Doyle-Cooper C, Cooper AB, Doores KJ, Aoki-Ota M, Le K, Schief WR, Wyatt RT, Burton DR, Nemazee D.  2013.  B cells from knock-in mice expressing broadly neutralizing HIV antibody b12 carry an innocuous B cell receptor responsive to HIV vaccine candidates.. J Immunol. 191(6):3179-85.
Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee J H, Cupo A, Korzun J, Derking R, van Montfort T, Julien J-P et al..  2013.  Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.. Proc Natl Acad Sci U S A. 110(45):18256-61.
Lyumkis D, Julien J-P, de Val N, Cupo A, Potter CS, Klasse P-J, Burton DR, Sanders RW, Moore JP, Carragher B et al..  2013.  Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.. Science. 342(6165):1484-90.
Doyle-Cooper C, Hudson KE, Cooper AB, Ota T, Skog P, Dawson PE, Zwick MB, Schief WR, Burton DR, Nemazee D.  2013.  Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10.. J Immunol. 191(6):3186-91.
Ferguson AL, Mann JK, Omarjee S, Ndung'u T, Walker BD, Chakraborty AK.  2013.  Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design.. Immunity. 38(3):606-17.
Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, Doores KJ, Hangartner L, Le K, Sok D, Jardine J et al..  2012.  Anti-HIV B Cell lines as candidate vaccine biosensors.. J Immunol. 189(10):4816-24.
Dosenovic P, Soldemo M, Scholz JL, O'Dell S, Grasset EK, Pelletier N, Karlsson MCI, Mascola JR, Wyatt RT, Cancro MP et al..  2012.  BLyS-mediated modulation of naive B cell subsets impacts HIV Env-induced antibody responses.. J Immunol. 188(12):6018-26.
Burton DR, Poignard P, Stanfield RL, Wilson IA.  2012.  Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.. Science. 337(6091):183-6.
Cheng C, Wang L, Wang LS, Gall JGD, Nason M, Schwartz RM, McElrath JM, DeRosa SC, Hural J, Corey L et al..  2012.  Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.. PLoS One. 7(4):e33969.
Ahmed FK, Clark BE, Burton DR, Pantophlet R.  2012.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.. Vaccine. 30(5):922-30.
Frahm N, DeCamp AC, Friedrich DP, Carter DK, Defawe OD, Kublin JG, Casimiro DR, Duerr A, Robertson MN, Buchbinder SP et al..  2012.  Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.. J Clin Invest. 122(1):359-67.
Haynes BF, Gilbert PB, McElrath JM, Zolla-Pazner S, Tomaras GD, Alam MS, Evans DT, Montefiori DC, Karnasuta C, Sutthent R et al..  2012.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.. N Engl J Med. 366(14):1275-86.
Barouch DH, Klasse P J, Dufour J, Veazey RS, Moore JP.  2012.  Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.. Proc Natl Acad Sci U S A. 109(22):8694-8.
Wilkinson P, Filali-Mouhim A, Li S, Ahlers J, Schatzle J, Pulendran B, Sekaly R-P, Cameron MJ.  2012.  An open-ended plea for the development of a global database of HIV vaccine responses.. Curr Opin HIV AIDS. 7(1):10-6.
Mouquet H, Nussenzweig MC.  2012.  Polyreactive antibodies in adaptive immune responses to viruses.. Cell Mol Life Sci. 69(9):1435-45.